Contraindications

The Renew® NCP-5 is contraindicated in the treatments of patients who have a history of the following:

  • Any surgical intervention within 6 weeks before ECP treatment.
  • Cardiac catheterization within 1-2 weeks before ECP treatment.
  • Uncontrolled arrhythmia or controlled arrhythmias that could interfere with ECP inflation and deflation triggering.
  • Dual chamber pacemakers with atrial pacing may interfere with ECP inflation timing sequence. This should be addressed prior to treatment.
  • Aortic insufficiency (regurgitation can prevent diastolic augmentation).
  • Severe pulmonary disease.
  • Limiting peripheral vascular disease involving the ileofemoral arteries.
  • Deep-vein thrombophlebitis (risk of thromboembolus).
  • Severe hypertension (≥ 180 mm Hg systolic or ≥ 110 diastolic).
  • Limiting peripheral vascular disease involving the ileofemoral arteries.
  • Deep-vein thrombophlebitis (risk of thromboembolus).
  • Bleeding disorders.
  • Patients undergoing major anti-coagulation therapy (such as Heparin therapy or Coumadin® therapy) with PT > 1.5.
  • Heart rates less than 35 or more than 125 beats per minute. (Patients with these heart rates should be evaluated and treated prior to ECP treatments).
  • Presence of abdominal aortic aneurysm.
  • Presence of local infection, vasculitis of the extremities.
  • Pregnant women and women of childbearing age who do not have a negative pregnancy test.
  • Presence of a burn, open wound, or bone fracture on any limb subject to ECP treatment.

COUMADIN® is a registered trademark of Bristol-Myers Squibb Pharma Company.

Man doing situps